Literature DB >> 16794100

High dose methylprednisolone in the immediate management of acute, blunt spinal cord injury: what is the current practice in emergency departments, spinal units, and neurosurgical units in the UK?

A E Frampton1, C A Eynon.   

Abstract

BACKGROUND: The National Acute Spinal Cord Injuries Studies and the Cochrane Review advocate the administration of high dose methylprednisolone following acute traumatic spinal cord injury. However, controversy surrounds its use and approaches between different units are often inconsistent.
METHODS: A questionnaire was sent to all emergency departments receiving major trauma and all specialist neurosurgical and spinal units in the UK to determine the current practice regarding the use of high dose methylprednisolone in the immediate management of acute, blunt spinal cord injuries.
RESULTS: Of 250 emergency departments, 187 replied to the questionnaire. Twelve of the 26 departments with a neurosurgical or spinal service on site stated they received consistent advice from specialist teams. Sixty four departments had a written policy regarding the treatment of spinal injuries, which in 51 departments contained advice about the administration of methylprednisolone. Of the 128 departments who gave methylprednisolone, 88 did so only on the advice of a specialist team, with the remaining 40 giving steroids immediately on identification of the injury. Ten out of 11 spinal units replied, of whom only two advised the used of steroids. Of the 34 neurosurgical units approached, seven out of 17 responders had a policy recommending the use of steroids. Of the 10 units who did not consistently recommend the use of steroids, seven had practise that varied between consultants.
CONCLUSION: Currently practice varies in the UK regarding the immediate use of methylprednisolone after spinal injury. Clear guidelines need to be established to achieve a more consistent approach.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794100      PMCID: PMC2579551          DOI: 10.1136/emj.2005.032698

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  19 in total

1.  Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Corticosteroids in acute spinal cord injury.

Authors:  P Wallman; K Mackway-Jones
Journal:  J Accid Emerg Med       Date:  2000-05

Review 2.  The role of steroids in acute spinal cord injury: an evidence-based analysis.

Authors:  R J Hurlbert
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

3.  A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury.

Authors:  W P Coleman; D Benzel; D W Cahill; T Ducker; F Geisler; B Green; M R Gropper; J Goffin; P W Madsen; D J Maiman; S L Ondra; M Rosner; R C Sasso; G R Trost; S Zeidman
Journal:  J Spinal Disord       Date:  2000-06

4.  Questionnaire survey of the views of the delegates at the European Cervical Spine Research Society meeting on the administration of methylprednisolone for acute traumatic spinal cord injury.

Authors:  S Molloy; M Price; A T Casey
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

5.  Is the role of steroids in acute spinal cord injury now resolved?

Authors:  D Short
Journal:  Curr Opin Neurol       Date:  2001-12       Impact factor: 5.710

Review 6.  Pharmacological therapy after acute cervical spinal cord injury.

Authors:  M N Hadley; B C Walters; P A Grabb; N M Oyesiku; G J Przybylski; D K Resnick; T C Ryken
Journal:  Neurosurgery       Date:  2002-03       Impact factor: 4.654

7.  Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.

Authors:  M B Bracken; M J Shepard; T R Holford; L Leo-Summers; E F Aldrich; M Fazl; M Fehlings; D L Herr; P W Hitchon; L F Marshall; R P Nockels; V Pascale; P L Perot; J Piepmeier; V K Sonntag; F Wagner; J E Wilberger; H R Winn; W Young
Journal:  JAMA       Date:  1997-05-28       Impact factor: 56.272

8.  Failure to administer methylprednisolone for acute traumatic spinal cord injury-a prospective audit of 100 patients from a regional spinal injuries unit.

Authors:  S Molloy; F Middleton; A T H Casey
Journal:  Injury       Date:  2002-09       Impact factor: 2.586

Review 9.  High-dose methylprednisolone for acute closed spinal cord injury--only a treatment option.

Authors:  H Hugenholtz; D E Cass; M F Dvorak; D H Fewer; R J Fox; D M S Izukawa; J Lexchin; S Tuli; N Bharatwal; C Short
Journal:  Can J Neurol Sci       Date:  2002-08       Impact factor: 2.104

10.  Why do you prescribe methylprednisolone for acute spinal cord injury? A Canadian perspective and a position statement.

Authors:  R J Hurlbert; R Moulton
Journal:  Can J Neurol Sci       Date:  2002-08       Impact factor: 2.104

View more
  3 in total

Review 1.  A review: the role of high dose methylprednisolone in spinal cord trauma in children.

Authors:  Janine N Pettiford; Jai Bikhchandani; Daniel J Ostlie; Shawn D St Peter; Ronald J Sharp; David Juang
Journal:  Pediatr Surg Int       Date:  2011-10-13       Impact factor: 1.827

Review 2.  Worldwide Steroid Prescription for Acute Spinal Cord Injury.

Authors:  Asdrubal Falavigna; Francine W Quadros; Alisson R Teles; Chung Chek Wong; Giuseppe Barbagallo; Darrel Brodke; Abdulaziz Al-Mutair; K Daniel Riew
Journal:  Global Spine J       Date:  2018-02-11

3.  Mortality and morbidity after high-dose methylprednisolone treatment in patients with acute cervical spinal cord injury: a propensity-matched analysis using a nationwide administrative database.

Authors:  Hirotaka Chikuda; Hideo Yasunaga; Katsushi Takeshita; Hiromasa Horiguchi; Hiroshi Kawaguchi; Kazuhiko Ohe; Kiyohide Fushimi; Sakae Tanaka
Journal:  Emerg Med J       Date:  2013-02-28       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.